{"analyses":[{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.66","estimateComment":"Reference level = 70.2 Gy arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.41","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"5","value":"3.5"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"3","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"751"},{"groupId":"OG001","value":"748"}],"units":"Participants"}],"description":"Failure time is defined as time from randomization to the date of progression (increase in palpable abnormality), failure of regression of the palpable tumor by two years, and redevelopment of a palpable abnormality after complete disappearance of previous abnormalities. Failure rates are estimated by the cumulative incidence method. Patients last know to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"70.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.","id":"OG000","title":"70.2 Gy"},{"description":"79.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.","id":"OG001","title":"79.2 Gy"}],"paramType":"NUMBER","populationDescription":"All eligible patients who have not withdrawn consent","reportingStatus":"POSTED","timeFrame":"From randomization to date of failure (local progression) or death or last follow-up. Analysis occurs at the same time as the primary endpoint.","title":"Local Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}